Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25666154 | 0.88 | MMP1 (0.39) | HPGDSL3MBTL1MAPTALDH1A1MMP1 | |
| SCHEMBL25666179 | 0.88 | HPGDS (0.40) | HPGDSL3MBTL1SMN1; SMN2MAPTTDP1 | |
| SCHEMBL18993738 | 0.88 | SMN1; SMN2 (0.41) | FOLH1L3MBTL1SMN1; SMN2MAPTTDP1 | |
| SCHEMBL867483 | 0.88 | SMN1; SMN2 (0.41) | FOLH1L3MBTL1SMN1; SMN2MAPTTDP1 | |
| SCHEMBL18993737 | 0.88 | SMN1; SMN2 (0.41) | FOLH1L3MBTL1SMN1; SMN2MAPTTDP1 | |
| SCHEMBL28694265 | 0.87 | MAPT (0.43) | FOLH1L3MBTL1SMN1; SMN2MAPTTDP1 | |
| SCHEMBL25666189 | 0.87 | MMP1 (0.45) | MAPTCYP2C9CYP2C19MMP1MMP2 | |
| SCHEMBL102846 | 0.86 | HPGDS (0.43) | HPGDSSMN1; SMN2MAPTALDH1A1POLB | |
| SCHEMBL9565258 | 0.85 | SMN1; SMN2 (0.42) | FOLH1L3MBTL1SMN1; SMN2MAPTTDP1 | |
| SCHEMBL29498305 | 0.85 | MAPT (0.54) | FOLH1L3MBTL1SMN1; SMN2MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115521254-B | Indanterol derivative and preparation method and application thereof | 中国药科大学 | 2024-05-31 | — | — | CN | disclosed |
| CN-116555205-A | Asymmetric reduction method of carbonyl by using carbonyl reductase and mutant thereof | 上海合全药业股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-115925623-A | Small molecule inhibitor and preparation method and application thereof | 中国药科大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-115636784-A | LYW-1 derivative and preparation method and application thereof | 中国药科大学 | 2023-01-24 | — | — | CN | disclosed |
| CN-115521254-A | Indanterol derivative and preparation method and application thereof | 中国药科大学 | 2022-12-27 | — | — | CN | disclosed |
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2022-09-20 | — | — | US | disclosed |
| EP-3256464-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2022-05-11 | — | — | EP | disclosed |
| EP-3256464-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2022-05-11 | — | — | EP | disclosed |
| CN-110087729-B | Bifunctional compound with quaternary ammonium salt structure | 北京硕佰医药科技有限责任公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-113544121-A | Heterocyclic derivative with beta 2 receptor agonistic and M receptor antagonistic activities and medical application thereof | 中国医药研究开发中心有限公司 | 2021-10-22 | — | — | CN | disclosed |
| WO-2004089892-A2 | DIARYLMETHYL AND RELATED COMPOUNDS HAVING BETA2 ANDRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004074812-A2 | LIBRARY OF BIPHENYL DERIVATIVES USEFUL FOR IDENTIFYING COMPOUNDS HAVING BOTH BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074276-A1 | BIPHENYL DERIVATIVES HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074246-A2 | BIPHENYL DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-08-26 | — | — | US | disclosed |
| WO-2004016578-A2 | ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| US-RE33024-E | Bronchodilating 8-hydroxy-5-(1R)-1-hydroxy-2-(N-((1R)-2-(p-methoxyphenyl)-1-methylethyl)-amino)ethyl) carbostyril and intermediates thereof | TANABE SEIYAKU CO. LTD. (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0147719-B1 | NOVEL CARBOSTYRIL DERIVATIVE AND PROCESS FOR PREPARING SAME | Tanabe Seiyaku Co., Ltd. (JP) | 1989-07-26 | — | — | EP | disclosed |
| US-4579854-A | ADRENERGIC STIMULANTS | TANABE SEIYAKU CO., LTD. (JP) | 1986-04-01 | — | — | US | disclosed |
| EP-0147719-A2 | Novel carbostyril derivative and process for preparing same | Tanabe Seiyaku Co., Ltd. (JP) | 1985-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | AGTR2, AGTR1, ADRB2 | HPGDS 4395/4885FOLH1 4440/4885L3MBTL1 3971/4885 |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | ADRB1, ADRB2, ADRA2B | HPGDS 3030/4885FOLH1 3130/4885L3MBTL1 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.